Licensing agreement for OXiGENE, Inc. (SE/US) — USD 70 million

Carnegie acted as adviser to OXiGENE, Inc. in the negotiation and signing of a licensing and research co-operation agreement with Bristol Myers Squibb in respect of the continued development of OXiGENE, Inc.’s combretastatin technology. OXiGENE Inc. is a pharmaceutical development within cancer treatment.December, 1999.